Genetically-engineered mouse models (GEMMs) of cancer are increasingly being utilized to 28 assess putative driver mutations identified by large scale sequencing of human cancer 29 genomes. In order to accurately interpret experiments that introduce additional mutations, an 30 understanding of the somatic genetic profile and evolution of GEMM tumors is necessary. Here, 31
INTRODUCTION 45
Lung cancer remains the leading cause of cancer death worldwide, estimated to have caused 46 158,000 deaths in the US in 2015 (seer.cancer.gov). Lung adenocarcinoma is the most 47 common form of lung cancer, in both smokers and nonsmokers. Tobacco mutagens cause a 48 high mutation frequency in the somatic genomes of smoking-associated tumors, complicating 49 identification of the genetic drivers of tumor progression (1, 2).
An increasing number of 50 somatic alterations that can be targeted by existing drugs or by drug candidates have been 51 identified in lung adenocarcinoma, and several of these agents have demonstrated efficacy in 52 patients (3). 53
KRAS and EGFR are the most frequently mutated oncogenes in human lung 54 adenocarcinoma (1, 2, 4, 5). KRAS mutations are associated with a strong history of cigarette 55 smoking, whereas EGFR mutations are the most frequent oncogene alterations in lung cancers 56 from never-smokers (6). Our groups and others have generated genetically engineered mouse 57 models of EGFR-and KRAS-mutant lung adenocarcinoma (7-10). These models recapitulate 58 key features of the human disease, including histologic architecture and response and 59 resistance to conventional and targeted therapies (11, 12). Although individual mice develop 60 multifocal disease, only a subset of the primary Kras tumors progress to metastatic disease. A 61 distinct gene expression signature has been shown to distinguish metastatic from non-62 metastatic primary tumors in a Kras G12D -driven GEMM, suggesting that acquired genetic or 63 epigenetic alterations underlie metastatic progression (13). 64
Somatic genome evolution in tumors produced in GEMMs remains incompletely 65 characterized. Several studies have described the spectrum of acquired DNA copy number 66 alterations in murine models (14) (15) (16) (17) (18) (19) . Although these studies reached varying conclusions, it 67 appears that somatic alterations in DNA copy number, especially changes in copy number of 68 certain whole chromosomes, are a common somatic event during tumor evolution in GEMMs. 69 We also recently studied a GEMM of small cell lung cancer using exome and whole genome 70 sequencing. In this model, which is initiated by mutation of the p53 and retinoblastoma (Rb) 71 tumor suppressors, we identified recurrent alterations in the PTEN/PI3K pathway, in addition to 72 previously identified focal DNA amplifications targeting the Mycl1 oncogene (20-22). Taken  73 together, these studies suggest that, similar to human cancers, GEMM tumors can undergo 74 extensive genome remodeling during tumor progression, and that a subset of these acquired 75 events contributes to cancer progression. 76
The mutational landscape of carcinogen-induced murine lung adenocarcinomas was 77 also recently described and compared to that in tumors initiated by expression of an oncogenic 78
Kras allele (23). Not surprisingly, single nucleotide mutations, including Kras mutations, were 79 more frequently observed in carcinogen-induced tumors. In contrast, secondary DNA copy 80 number alterations were more prevalent in tumors arising in genetically-engineered mice. This 81 further suggests that the path of somatic alteration and selection during tumor progression 82 depends on the specific events that initiate tumorigenesis. As previously described, the 83 carcinogen-treated tumors acquired clonal oncogenic Kras mutations. However, it remains 84 unknown whether murine lung adenocarcinomas initiated by other oncogenic drivers, or those 85 harboring combined loss of the tumor suppressor p53, acquire similar or distinct patterns of 86 somatic alteration during tumor evolution and progression. Here, we describe the somatic 87 evolution of a panel of tumors and tumor-derived cell lines derived from genetically-engineered 88 mouse models of lung adenocarcinoma initiated by Kras, EGFR, and MYC (10, (24) (25) (26) . 89
90

RESULTS
91
Mouse models of lung adenocarcinoma acquire few somatic point mutations 92
We generated a panel of tumor specimens and tumor cell lines from GEMMs of EGFR-, 93 and MYC-mutant lung adenocarcinoma (Figure 1 ). We performed whole exome sequencing on 94 tumors and cell lines from these models in order to profile the spectrum of genomic alterations 95 acquired during tumorigenesis and progression (Tables 1, S1, S2) . 96 We initially focused on somatic point mutations. Several methods of mutation calling 97 have been developed but agreement among the various methods is poor (27); at the beginning 98 of our studies, there was no independent evaluation of which method had optimal sensitivity and 99 specificity. Evidence that aggregating calls from multiple methods improves performance was 100 recently described (23, 28 ). An added challenge was that the methods were developed to call 101 mutations in human tumors, and many had parameters (e.g. background mutation rate) that 102 were optimized for human samples. Therefore, we created a controlled dataset in order to 103 assess the performance of our variant-calling pipeline in a murine background by simulating 104 mixtures of tumor and normal DNA using exon capture of mixtures of germline DNA from 105 different inbred mouse strains ( Figure S1A ). 106
As a first step, we generated exon-capture sequencing libraries with tail DNA from 107 inbred C57BL/6 and 129S1/SvImJ mice. In order to simulate tumor subclonal heterogeneity and 108 contamination with infiltrating non-tumor stromal cells, we serially diluted the 129S1/SvImJ 109 library (mimicking "tumor DNA") into the C57BL/6 library (mimicking "normal DNA") ( Figure  110 S1A). The starting libraries and mixtures were sequenced to a median average depth of 132x 111 (range from 92x-205x). Somatic mutations were identified using both muTect (v1.1.4) and a 112 somatic mutation caller developed by our group (hereafter referred to as the HaJaVa caller) 113 based on the GATK UnifiedGenotyper with filtering to call somatic events (as described in detail 114 in the Methods sections) (29). Using this approach, individual germline polymorphisms can be 115 traced through the serially diluted libraries, mimicking somatic variant detection in tumors. This 116 dataset was used to estimate the false positive and false negative rates at decreasing allelic 117 fraction. 118
At the indicated depth of coverage, muTect was highly sensitive, particularly at low allelic 119 fractions that might be found in samples with a low fraction of tumor cells or as a result of 120 subclonal mutational events, but it exhibited a higher false positive rate. In contrast, the 121 HaJaVa caller exhibited a higher true-positive rate, but also a higher false negative rate at low 122 allelic fraction (Supplemental methods, Figure S1B- 
130
G12D
-based mouse models for whole exome sequencing (Table 1) We compared these datasets to available sequencing data from human lung 154 adenocarcinoma ( Figure 2E ). We observed a significantly fewer nonsynonymous mutations in 155 GEMM models than in either smoker-or nonsmoker -associated human lung adenocarcinomas 156 We also observed recurrent mutation of Pclo, which has been shown to be important for 177 axonal guidance during central nervous system development. PCLO, which was mutated in 178 21% of lung adenocarcinomas in the TCGA study, was also recently identified as a recurrently 179 mutated gene in liver cancers exhibiting a biliary phenotype (32). Knockdown of PCLO RNA in 180 human liver cancer cells led to an increase in cell migration. We identified two mutations in Pclo, (Table S4) . 189
None of these specific mutations has been identified in human cancers. Therefore, it is difficult 190 to determine if any of these represent driver events. However, mutations in many epigenetic 191 regulators in human tumors are not clustered into "hot spots," so it is premature to conclude that 192 these are passenger mutations in the mouse model. Recurrent mutations in the tumors were found in Kras (n=4, 2 G12V and 2 Q61R), Mll5 212 (n=2) and Ube3b (n=2). We previously described an oncogenic Kras mutation in an erlotinib-213 resistant murine tumor; however, such mutations have not been described in patients (12). Since a major mechanism of resistance to EGFR inhibitors is a secondary mutation in 231
), we examined the whole exome sequencing data to determine whether we 232 could detect reads corresponding to human EGFR (since the transgene encodes human 233 EGFR). Indeed, we unequivocally detected the EGFR T790M mutation in one erlotinib-resistant 234 tumor that we had previously shown to harbor this mutation. However, we cannot exclude 235 inadequate depth of sequencing of the human EGFR transgene as an explanation of our failure 236 to identify other cases of secondary T790M mutations of EGFR in these tumors, especially 237 since the exon capture probes target mouse sequences. 238
239
MYC model of lung adenocarcinoma 240
The low mutation rate observed in the Kras and EGFR-induced lung tumors prompted us to 241 hypothesize that tumors induced by strong oncogenic lung drivers might have a lower mutation 242 burden than tumors induced by a less potent lung oncogene. We therefore performed whole 243 exome sequencing of DNA from five lung adenocarcinomas that arose in a mouse model 244 initiated by overexpression of wild type human MYC, which has been shown to be a less potent 245 oncogene than mutant KRAS or EGFR in the murine lung (25).
MYC-induced tumors also 246 exhibited a low mutation frequency, comparable to that observed in Kras-induced mouse lung 247 adenocarcinomas (0.14 vs 0.07 mutations/Mb, P value=0.57 Figure 2A Given the low point mutation rates observed in the mouse tumors in our GEMM models, we 258 asked whether the tumors harbored alterations in chromosomal or subchromosomal copy 259 numbers. In order to examine somatic changes in DNA copy number in the GEMM tumors, we 260 analyzed the datasets from whole exome sequencing using validated computational methods 261 (36, 37). We first examined the Trp53 locus, which was anticipated to be deleted in the 262 unlikely to be true events. In particular, one signature observed was a set of breakpoints with 271 the same start and stop positions and in tumors that were matched to the same normal sample. 272
These are likely to be artifacts of variable coverage from sequencing of the normal (tail) DNA. 273
Another finding included regions with nearly balanced amplifications and deletions with 274 overlapping annotated duplication regions in the UCSC browser. These are likely to be copy 275 number polymorphisms (Table S5) . 276
Although the models we have studied all produce one histological tumor type, lung 277 adenocarcinoma, the tumors that develop in each GEMM show a distinct pattern of recurrent 278 DNA copy number gain or loss ( Figure 4A -C, Table S5 ).
Kras-driven tumors and cell lines 279 harbored recurrent gain of Chr6, consistent with prior studies of Kras-induced lung tumors (16, 280 17, 23, 38). In addition to extra copies of Chr6, we observed recurrent whole chromosome 281 amplification of Chr2, Chr15, and Chr19 (in ≥ 20% of samples), and whole chromosome loss of 282 Chr9 and Chr14 (Table S5 ). Since Chr6 carries the Kras locus, we determined the allelic 283 fraction with the G12D mutation; this analysis suggested that the chromosome with the 284 engineered G12D mutant, not the chromosome with the wild type allele, was responsible for the 285 gain in chromosome number ( Figure S4) . Similarly, the proto-oncogene Myc is on Chr 15, and 286 gain of copies of Chr 15 is the second most frequent whole chromosome alteration observed in 287 this model and consistent with previous work suggesting that Myc function may be necessary 288 for tumor maintenance in Kras-driven GEMMs (39). 289
Recurrent whole chromosome DNA copy number changes appeared to be less frequent 290 in the EGFR-driven GEMM (Figure 4 , Table S6 ) and a different pattern of changes was 291 observed. For unexplained reasons, an increased number of copies of Chr12 was the most 292 recurrent alteration. It is possible that the unmapped TetO-EGFR transgene is integrated in 293
Chr12; gain in copy number might then increase signaling from the EGFR oncogene. 294
We did not observe an anti-correlation between the frequency of point mutations and the 295 fraction of the genome affected by DNA copy number alterations, as previously described (23). 296
This might in part be due to the overall low mutational frequency observed in these tumors, 297
which is approximately an order of magnitude lower than observed in carcinogen-induced 298
models (mean of 185 mutations in urethane-induced and 728 in MNU-induced tumors) (23). 299
Therefore, it is possible that when higher mutation loads are present there is less selection for 300 large-scale DNA copy number alterations across the genome in these models. 301
Recent improvements in DNA sequencing technologies have spurred the genomic 303 characterization of many types of human cancers, including lung adenocarcinomas. These 304 datasets have revealed much information about the mutational profiles of this cancer, and 305 identified several novel putative oncogenes and tumor suppressors. However, unraveling the 306 complexity of these datasets and distinguishing driver and passenger mutations remain 307 significant challenges, particularly in highly mutated genomes such as smoking-associated lung 308 adenocarcinoma. In contrast, in this report, we have observed a very low mutation frequency in 309 EGFR-, Kras-and MYC-driven GEMM tumors, regardless of tumor genotype. The low mutation 310 frequency in the murine tumors is consistent with prior studies of other GEMMs and suggests 311 that the number of mutations necessary for the development and progression of invasive lung 312 adenocarcinomas in mice is small (19, 40). 313
We detected recurrent whole chromosome gains and losses in the EGFR and Kras-314 driven models. These observations raise the question of whether copy number alterations are 315 contributing to tumorigenesis in these models. Considering that we observed recurrent Chr6 316 amplification, which encodes the engineered Kras LSL-G12D allele as well as several components 317 of the MAPK signaling pathway, in Kras-driven models, we speculate that cooperating 318 oncogenes and or tumor suppressors located in the regions of whole chromosome gain or loss 319 indeed contribute to tumor progression. However, the identity of the driver events in the 320 amplified and deleted regions remains to be determined. These observations suggest that 321 amplification of the signal from the initiating oncogene may be the most important somatic event 322 in these models to drive tumor progression (38) . 323
Previous work also described changes in gene expression during tumor progression, 324
suggesting that epigenetic alterations contribute to progression in these models (13). The 325 detection of several mutations in transcriptional regulators and chromatin-remodeling factors in 326 our models (see Figure 3) is consistent with these findings, although we have not determined 327 directly whether any of the observed mutations accelerate tumor progression or lead to specific 328 changes in chromatin in these models. 329
We found evidence for clonal selection during the emergence of drug resistance and 330 during the generation of tumor-derived cell lines. Tumors harvested from mice with EGFR-331 mutant lung cancer harbored oncogenic lesions known to confer primary or acquired resistance 332 to TKIs (for example, Kras mutations and the EGFR T790M mutation, respectively). In addition, highlights the potency of this oncogene and strongly suggests that the initiating genetically-345 engineered allele is a critical determinant of acquired events in these models. 346
The overall non-synonymous mutation burden in human lung adenocarcinomas is 6.86 347 mutations/Mb (lung TCGA). This is approximately 50-fold higher than the median mutation 348 burden observed in any of the mouse lung adenocarcinomas studied here. In part, this is likely 349 to reflect the lack of carcinogen exposure. However, the mutation rate in never smokers (1.97 350 mutations/Mb) remains over 10-fold higher than that observed in our lung cancer models (4). 351
The rapid development of tumors in mice may also contribute to the reduced complexity of the 352 cancer genome in these models compared to human lung adenocarcinoma. As previously 353 described, the copy number profiles of mouse tumors were generally characterized by large-354 scale whole chromosome gains or losses (14, 15, 17, 18). In contrast, human tumors exhibited 355 both large-scale and focal amplifications and deletions, perhaps also reflecting differences in 356 carcinogen exposures in tumors in the two species (41). 357
Our findings have important implications for the optimal use and further development of 358 GEMMs, particularly considering the ease with which these modifications can be generated 359 using new genome editing methods (42-44). Although we have not sequenced to the extreme 360 depth necessary to identify mutations in very small subpopulations of tumor cells, the genomic 361 profile of these models appears to be much less complex than most human cancers. The 362 genomic complexity of lung cancer is at the heart of drug resistance and appears to be an 363 important determinant of the response to immune checkpoint inhibitors (45). 364
We previously reported that tumors in the Kras ; Trp53 fl/fl model exhibit very 365 modest immune cell infiltrates (46). This is consistent with very few neoantigens generated as a 366 result of the very low number of somatic mutations that arise during tumor development as we 367 describe here. However, expression of a strong T-cell antigen in the model induces a potent T-368 cell response, which is subsequently suppressed at later stages of tumor progression (46). 369 Therefore, it is important to consider the low mutation frequency exhibited in tumors in these 370
GEMMs when designing therapeutic studies or studies of drug resistance studies. At the same 371 time, the uniformity of the programmed somatic mutations and low acquired mutation frequency 372 observed in tumors in these models are important experimental strengths, making the models 373 well suited to reproducible mechanistic studies and genetic screening.
Efforts to model 374 genomic complexity in GEMMs, using mutagens, transposons, or engineered loss of DNA repair 375 pathways are approaches to further optimize GEMMs for studies of sensitivity and resistance to 376 therapies and could identify new drivers of progression and metastasis that cooperate with the 377 initiating engineered mutations. 378
METHODS: 379
Mouse models: 380
All animals studies were performed under approved IACUC protocols at MIT and MSKCC. 381
Tumor induction was performed in Kras ; p53
fl/fl and Kras LSL-G12D mice as previously 382 described with 2.5 X 10 4 lentivirus particles per animal (30). Tumors were isolated and tumor-383 derived cell lines were generated as previously described, for tumor-derived cell lines (13). 384
Histological analysis was performed on a piece of each tumor in order to assess tumor purity 385 and histological subtype of lung cancer. Tumors were induced in the TetO-EGFR L858R and 386
TetO-MYC models by feeding the mice doxycycline impregnated food as previously described 387 (10). 388 389 Exome Sequencing: 390 DNA was purified from tumor tissue and tumor cell lines using standard methods. Sonication of 391 2ug genomic DNA was performed using a Diagenode Bioruptor, and size selection was 392 performed using dual selection using AMPure beads as previously described (47). Exon 393 capture was performed using Roche SeqCap EZ all-exon mouse kits. Post-capture libraries 394
were sequenced on an Illumina HiSeq instrument. 395
396
Variant Calling: 397
The pipeline to call somatic mutations was predominately composed of standard programs that 398 have been used in human tumor analysis with the addition of a custom caller that was optimized 399 to reduce false positives at the expense of some sensitivity to low allele frequency events. The 400 final mutation list was the intersection of these two calling algorithms in the hope that artifacts 401 given rise to false positives in one would be filtered out by the other. 402
403
Raw sequence files were first pre-processed to remove the sequencing adapters. Then clipped 404 reads were mapped to the standard mm9 genome for the Kras model or to mm9+transGene 405 (hEGFR or hMYC) hybrid genomes for the EGFR and MYC models. BWA ALN (version 0.5) 406 was used to make maps. The reads were marked with read groups and sorted, then duplicates 407 were removed using the PICARD toolkit. These initial bam files were post-processed using the 408 standard GATK packages; indel realignment was followed by base quality recalibration. The 409 post-processed bam files were then called using two separate mutation callers: MuTect (v1. 
